R Squared’s Stoke Therapeutics STOK Stock Holding History

R Squared’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-440	Closed	-$4.85K	–	1355
2024 Q4	$4.85K	Buy	+440	New	+$5.41K	﹤0.01%	1318

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

R Squared's STOK Position: Q1 2025 in Review

R Squared sold out of Stoke Therapeutics (STOK) in Q1 2025, closing a stake of 440 shares — an estimated $4.85K sold.

R Squared first reported a position in STOK in Q4 2024 and held it in 1 quarter. The position peaked at $4.85K in Q4 2024. 126 funds tracked by Wall St. Rank hold STOK as of Q1 2025.

R Squared reported no remaining Stoke Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 440 Stoke Therapeutics shares in Q1 2025, an estimated $4.85K.
R Squared first reported a position in Stoke Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Stoke Therapeutics position peaked at $4.85K in Q4 2024.
126 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.